← All Compounds research only

Selank

Neuropeptide Analog
Last updated: 1/23/2026 Last reviewed: 1/23/2026

At a Glance

Selank is a peptide analog discussed in anxiolytic contexts, with a body of literature that is regionally concentrated and not always easily accessible in English. One comparative clinical report (Russian-language) describes selank versus phenazepam in anxiety disorders. [PMID: 25176261]

⚠️ Research Status: Selank is not an approved medication in many jurisdictions. This page is educational and intentionally does not include protocols/dosing.


Mechanism of Action (TBD)

Mechanistic proposals vary (e.g., neuroimmune and neurotransmitter-related framing) and should be grounded in primary sources when making any specific claim.


Evidence Summary

Low Confidence Observational 3-10 Years

Comparative clinical report (Russian-language) describes anxiolytic effects and tolerability outcomes in the studied setting. [PMID: 25176261]


Safety & Unknowns

  • Clinical evidence quality and reporting varies by source and region.
  • Safety and efficacy cannot be generalized from limited, hard-to-audit sources.

Regulatory Status

RegionStatus
United States (FDA)Not approved
European Union (EMA)Not approved
WADACheck current list (status may change)

Changelog

DateChange
2026-01-23Added dossier and linked primary literature